[关键词]
[摘要]
新生血管性青光眼(NVG)是眼科常见的一种难治性青光眼，通常继发于视网膜中央静脉阻塞(CRVO)、糖尿病视网膜病变(DR)、陈旧性视网膜脱离、眼部肿瘤等。既往治疗主要包括：全视网膜光凝(PRP)、药物、抗青光眼手术或睫状体破坏术，但治疗效果不佳。随着抗血管内皮生长因子(VEGF)药物的不断发展和运用，抗VEGF药物联合治疗逐渐被提出，NVG手术成功率显著增加，NVG得以控制。本文主要围绕NVG近年来的治疗进展进行详细综述。
[Key word]
[Abstract]
Neovascular glaucoma(NVG)is a common refractory glaucoma in ophthalmology, which is usually secondary to central retinal vein occlusion(CRVO), diabetic retinopathy(DR), long-standing retinal detachment, ocular tumors, etc. Previous treatments mainly included panretinal photocoagulation(PRP), drugs, anti-glaucoma surgery or ciliary destruction, but the therapeutic effect was unsatisfactory. With the continuous development and application of anti-vascular endothelial growth factor(VEGF)drugs, combination therapy of anti-vascular endothelial growth factor(VEGF)drugs has been proposed gradually, and the success rate of NVG surgery has been increased significantly, and NVG can be controlled. The treatment progress of NVG in recent years will be described in detail.
[中图分类号]
[基金项目]
湖北省卫生计生委重点支撑项目(No.WJ2017Z004)
